Skip to content

Asset turnover at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.4×0.0×
Janux Therapeutics logo
Janux TherapeuticsJANX
0.0×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
Immunome logo
ImmunomeIMNM
0.0×

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's asset turnover?
CytomX Therapeutics (CTMX) reported asset turnover of 0.2× in Q1 2026.
How has CytomX Therapeutics's asset turnover changed year-over-year?
CytomX Therapeutics's asset turnover decreased by 85.1% year-over-year, from 1× to 0.2×.
What is the long-term trend for CytomX Therapeutics's asset turnover?
Over 5 years (2020 to 2025), CytomX Therapeutics's asset turnover has grown at a 23.4% compound annual growth rate (CAGR), from 0.2× to 0.6×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.